Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 736M 644M 594M 548M 1.04B 70.18B 1.06B 7.09B 2.79B 34.57B 2.76B 2.7B 119B P/E 2026 *
3.79x
P/E 2027 * 3.62x
Enterprise Value 736M 644M 594M 548M 1.04B 70.18B 1.06B 7.09B 2.79B 34.57B 2.76B 2.7B 119B EV / Sales 2026 *
1.6x
EV / Sales 2027 * 1.54x
Free-Float
96.84%
Yield 2026 *
-
Yield 2027 * -
1 day-4.28%
1 week+3.23%
Current month+6.18%
1 month+33.43%
3 months+23.14%
6 months+10.10%
Current year+32.64%
1 week 4.27
Extreme 4.27
4.88
1 month 3.49
Extreme 3.49
4.88
Current year 2.95
Extreme 2.95
5.78
1 year 0.67
Extreme 0.6701
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 11/03/2021
Director of Finance/CFO 44 14/05/2026
Chief Tech/Sci/R&D Officer - 31/03/2024
Director TitleAgeSince
Director/Board Member 68 03/06/2021
Chairman 61 31/03/2019
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap.
07-06Sell

Chief Financial Officer

-127,890 0.0777%
06-15Free

Director

63,481 0.0386%
06-15Free

Director

63,481 0.0386%
Change 5-day change 1-year change 3-year change Capi.($)
-4.28%+3.23%+476.11%-56.39% 736M
-1.22%-4.65%+47.04%+12.35% 305B
+0.07%-4.09%+22.06%-4.22% 69.44B
-3.08%-4.09%+32.22%+104.18% 9.04B
-1.23%-0.84%+6.26%+1.52% 8.56B
+2.74%-4.41%-16.77%+12.26% 4.3B
+1.60%-9.66%+14.44%+27.14% 4.09B
+1.63%-2.70%-38.89%+27.08% 3.4B
-0.59%+0.85%+46.23%+62.45% 2.81B
+2.24%-2.33%+11.41%-21.98% 2.14B
Average -0.21%-1.23%+60.01%+16.44% 40.96B
Weighted average by Cap. -0.93%-3.39%+40.49%+11.65%

Financials

2026 *2027 *
Net sales 459M 402M 371M 342M 650M 43.82B 661M 4.43B 1.74B 21.59B 1.73B 1.69B 74.22B 478M 418M 386M 356M 676M 45.62B 688M 4.61B 1.81B 22.47B 1.8B 1.76B 77.26B
Net income 188M 165M 152M 140M 266M 17.95B 271M 1.81B 713M 8.84B 707M 691M 30.4B 210M 184M 169M 156M 297M 20.02B 302M 2.02B 794M 9.86B 788M 771M 33.9B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
10/07/26 US$4.470 -4.28% 2,775,825
09/07/26 US$4.670 -2.10% 3,141,607
08/07/26 US$4.770 +6.71% 4,987,325
07/07/26 US$4.470 +2.05% 3,479,056
06/07/26 US$4.380 +1.15% 3,001,622
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.470USD
Average target price
6.100USD
Spread / Average Target
+36.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock